Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer

2016 ◽  
Vol 20 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Lisha Wang ◽  
Fei Ren ◽  
Qifeng Wang ◽  
Lee Ann Baldridge ◽  
M. Francesca Monn ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Immunohistochemical Expression ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer

2018 ◽  
Vol 9 (23) ◽  
pp. 4325-4333 ◽  
Author(s):  
Xiao-Li Wei ◽  
Qi-Nian Wu ◽  
Dong-liang Chen ◽  
Zhao-Lei Zeng ◽  
Jia-Bin Lu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Heterogeneous Expression

scholarly journals Gastrointestinal cancer treatment with immune checkpoint inhibitors

2021 ◽  
Vol 64 (5) ◽  
pp. 342-348
Author(s):  
Jin Won Kim
Keyword(s):  
Colorectal Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Line Treatment ◽  
Gastrointestinal Cancers ◽  
First Line ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
First Line Treatment

Immuno-oncological treatment approaches, particularly with the use of immune checkpoint inhibitors such as antiprogrammed death 1 (PD-1)/programmed death ligand 1 antibody or anti-cytotoxic T-lymphocyte associated protein 4 antibody, have become the standard treatment for gastrointestinal cancers. However, gastrointestinal cancers show an overall modest tumor response to immune checkpoint inhibitors. Nevertheless, subgroups such as tumors that are DNA mismatch repair-deficient or have high microsatellite instability particularly benefit from immune checkpoint inhibitors. Even in the first-line setting for colorectal cancer, the clinical efficacy of pembrolizumab, an anti–PD-1 antibody, was superior to that of chemotherapy. Recently, a combination of atezolizumab, an anti-programmed death ligand 1 antibody, and bevacizumab was approved as the first-line treatment for hepatocellular carcinoma, and was reported as superior to sorafenib. Nivolumab, an anti–PD-1 antibody that is added to chemotherapy as the first-line treatment for gastric cancer, resulted in longer survival compared with chemotherapy alone. Further studies are ongoing to investigate additional immune checkpoint inhibitors for other gastrointestinal cancers. This review aims to provide an overview of the results of clinical trials for immune checkpoint inhibitors in gastrointestinal cancers, including colorectal cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, and biliary tract cancer.

The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation

2020 ◽  
Vol 29 (1) ◽  
pp. 76-81 ◽  
Author(s):  
Angels Barberà ◽  
Ruth Marginet Flinch ◽  
Montserrat Martin ◽  
Jose L. Mate ◽  
Albert Oriol ◽  
...  
Keyword(s):  
Immunohistochemical Expression ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

Prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with stage III colorectal cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3568-3568 ◽  
Author(s):  
Shigehiro Koganemaru ◽  
Naoko Inoshita ◽  
Yuji Miura ◽  
Yudai Fukui ◽  
Yukinori Ozaki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Value ◽  
Stage Iii ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I—Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications

2017 ◽  
Vol 142 (1) ◽  
pp. 17-25 ◽  
Author(s):  
Esmeralda Celia Marginean ◽  
Barbara Melosky
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Mismatch Repair ◽  
Tnm Classification ◽  
Therapy Response ◽  
Poor Response ◽  
Predictive Biomarker ◽  
Developed Countries ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

Context.— Colorectal cancer (CRC) represents the third most-common cancer in developed countries and is a leading cause of cancer deaths worldwide. Two recognized pathways contribute to CRC development: a more-common chromosomal instability pathway and, in 15% of cases, a deficient mismatch repair or microsatellite instability–high (MSI-H) pathway. The MSI-H CRC can be associated with somatic or germline mutations. Microsatellite status has been recognized as a prognostic and predictive biomarker. Objectives.— To summarize the molecular pathways of CRC, with an emphasis on the MSI (mismatch repair) pathway; the recommended MSI testing algorithms and interpretation; and the prognostic and predictive role of MSI-H status in personalized treatment, including adjuvant chemotherapy, targeted therapy, and immune checkpoint inhibitor therapy. Data Sources.— A PubMed (US National Library of Medicine, Bethesda, Maryland) review was performed for articles pertaining to CRC, MSI and mismatch repair systems, molecular classification, immune response, programmed death receptor-1/programmed death ligand-1, and immunotherapy. Conclusions.— Although the TNM classification of malignant tumor stage remains the key determinant of CRC prognosis and treatment, there are considerable stage-independent, interindividual differences in clinical outcome and therapy response by patients. In addition, MSI-H status has an important role in CRC management and can be reliably detected by molecular and immunohistochemistry techniques and genetic testing. Efforts must be made to identify whether MSI-H CRC is germline or sporadic to ensure appropriate treatment, accurate prognosis, and risk assessment for relatives. Microsatellite status has been recognized as a good prognostic indicator and is predictive of a poor response to 5-fluorouracil–based chemotherapy and a good response to programmed death ligand-1 inhibitor pembrolizumab in metastatic/refractory MSI-H CRC.

Sign in / Sign up

Export Citation Format

Share Document